Everyone is aware of the troubling growth trend in the illicit pharmaceutical trade, and while we all agree that more needs to be done to protect patients, serialisation compliance will only be part of the solution. Neither Governments nor drug companies should be in any doubt - serialisation by itself will not be enough to safeguard the pharma supply chain and prevent illicit pharmaceutical trade, and thus, patient health risk.
- Discuss where item-level serialisation fits into the patient health protection strategy, and why it is not a solution in itself
- Analyse what combination of technologies is needed to fight counterfeiting
- Examine the impact of pharmaceutical product identification and traceability at the formulation level, and as a result, how pharmaceutical companies can better monitor patient impact